4D Molecular Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
FDMT$12.25+8.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Unaudited Financial Statements Condensed Balance Sheets as of March 31, 2024 and December 31, 2023
Condensed Balance Sheets (Unaudited)
(In thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $275,594 | $249,108 |
| Marketable securities | 250,317 | 39,124 |
| Prepaid expenses and other current assets | 9,678 | 8,356 |
| Total current assets | 535,589 | 296,588 |
| Marketable securities, long-term | 62,942 | 10,954 |
| Property and equipment, net | 19,464 | 20,126 |
| Operating lease right-of-use assets, net | 11,118 | 11,539 |
| Other assets | 771 | 684 |
| Total assets | $629,884 | $339,891 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $4,217 | $3,515 |
| Accrued and other current liabilities | 9,013 | 12,014 |
| Deferred revenue | — | 273 |
| Operating lease liabilities, current portion | 3,173 | 3,149 |
| Total current liabilities | 16,403 | 18,951 |
| Deferred revenue, net of current portion | 1,322 | 972 |
| Derivative liability | 369 | 369 |
| Operating lease liabilities, long-term portion | 10,998 | 11,522 |
| Other liabilities | 231 | 248 |
| Total liabilities | 29,323 | 32,062 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value, 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 51,157,388 and 43,075,218 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 5 | 4 |
| Additional paid-in-capital | 1,048,393 | 723,136 |
| Accumulated other comprehensive gain (loss) | (109) | 16 |
| Accumulated deficit | (447,728) | (415,327) |
| Total stockholders’ equity | 600,561 | 307,829 |
| Total liabilities and stockholders’ equity | $629,884 | $339,891 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.